Bonell Patiño-Escobar, MD
Postdoctoral Scholar
Laboratory Medicine
School of Medicine

Awards

Show all (1) Hide

• 2022 MMRF Research Fellowship, Multiple Myeloma Research Foundation, 2022-2025

Education & Training

Show all (3) Hide

• Fellowship Hematology Hospital de San José 2016
• Residency Internal Medicine Hospital Universitario Clinica San Rafael 2014
• MD Fundacion Universitaria Juan N. Corpas 2009

Publications (11)

Top publication keywords:
Multiple MyelomaProteasome InhibitorsMembrane Cofactor ProteinDrug Resistance, NeoplasmCell Line, TumorAntineoplastic AgentsImmunotherapyHSP70 Heat-Shock ProteinsActiniumAntineoplastic Agents, ImmunologicalMitochondriaZirconiumLeukemia, Myeloid, AcuteProteostasisRadioisotopes

• CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y,…
• Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
  bioRxiv : the preprint server for biology 2024 Kasap C, Izgutdina A, Patiño-Escobar B, Kang A, Chilakapati N, Akagi N, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Wicaksono G, …
• Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target.
  Nature cancer 2023 Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano …
• Overcoming proteasome inhibitor resistance in the immunotherapy era.
  Trends in pharmacological sciences 2023 Patiño-Escobar B, Talbot A, Wiita AP
• Unraveling the surface proteomic profile of multiple myeloma to reveal new immunotherapeutic targets and markers of drug resistance.
  Cell stress 2022 Patiño-Escobar B, Ferguson ID, Wiita AP

Show all (6 more) Hide

• Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
  Cell chemical biology 2022 Ferguson ID, Lin YT, Lam C, Shao H, Tharp KM, Hale M, Kasap C, Mariano MC, Kishishita A, Patiño Escobar B, Mandal K, Steri V, Wang D, Phojanakong P, Tuomivaara ST, Hann B, Driessen C, Van Ness B, …
• The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
  Nature communications 2022 Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL…
• FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma.
  Blood advances 2021 Bigley AB, Spade S, Agha NH, Biswas S, Tang S, Malik MH, Dai L, Masoumi S, Patiño-Escobar B, Hale M, DiPierro G, Martell R, Hann B, Shah N, Wiita AP, Liu X
• CD38: From Positive to Negative Expression after Daratumumab Treatment.
  Cureus 2020 Patiño-Escobar B, Ramos R, Linares M, Mejía A, Alcalá S
• Niemann-Pick Disease: An Approach for Diagnosis in Adulthood.
  Cureus 2019 Patiño-Escobar B, Solano MH, Zarabanda L, Casas CP, Castro C
• Myelomastocytic Blast Cell Crisis in Resistant Tyrosine Kinase Inhibitor Chronic Myelogenous Leukemia: Case Report and Review of Literature.
  Cureus 2019 Martinez-Cordero H, Patiño-Escobar B, Enciso LJ, Otero DM, Spirko P